Pre-dispute Agreements to Arbitrate Sexual Harassment and Sexual Assault Claims Will Be Voidable Pursuant to Federal Legislation
Client Alert | 1 min read | 03.02.22
On February 10, 2022, Congress passed H.R. 4445, titled the “Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act of 2021.” The legislation would amend the Federal Arbitration Act (FAA) to render pre-dispute employment arbitration agreements voidable at the election of the employee for all sexual harassment and sexual assault claims. Employees will still be permitted to choose to arbitrate these claims. The legislation would also render pre-dispute employee waivers of the right to bring such claims jointly or on a class basis voidable.
Courts—not arbitrators—decide under federal law whether a claim constitutes sexual harassment or sexual assault subject to H.R. 4445, even if the arbitration agreement includes a provision delegating these decisions to the arbitrator. The law will apply to any sexual harassment or sexual assault claim that arises on or after its date of enactment.
While H.R. 4445 currently awaits President Biden’s signature, there is little doubt that he will sign it. On February 1, 2022, President Biden issued a Statement of Administration Policy encouraging the passage of the bill. In anticipation of the enactment of this law, employers should review and evaluate their current policies concerning the enforcement of employment arbitration agreements to make sure such agreements are not enforced with respect to claims exempt from mandatory arbitration under federal law. Additionally, for new employee arbitration agreements, employers should consider adding a specific carve-out for sexual harassment and sexual assault claims.
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today